8-K: RAPT Therapeutics Faces Nasdaq Delisting Threat Over Sub-$1.00 Share Price; Proposes Reverse Stock Split

RAPT Therapeutics, Inc. received a Nasdaq notification for failing to meet the minimum $1.00 bid price requirement, prompting a proposed one-for-eight reverse stock split to regain compliance.

Summary

• RAPT Therapeutics, Inc. (the "Company") received a notification from the Nasdaq Listing Qualifications Department on May 21, 2025, indicating non-compliance with the minimum $1.00 closing bid price requirement (Nasdaq Rule 5450(a)(1)).
• The Company's common stock average closing bid price was below $1.00 per share for 30 consecutive trading days.
• This notice has no immediate impact on the listing of the Company's common stock, which will continue to be listed and traded on Nasdaq.
• RAPT has 180 calendar days, until November 17, 2025 (the "Compliance Date"), to cure the deficiency and regain compliance.
• To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days before the Compliance Date.
• The Company's Board of Directors has approved an amendment to its Certificate of Incorporation to effect a one-for-eight reverse stock split, subject to stockholder approval at the Annual Meeting on May 29, 2025.
• One of the primary purposes of the proposed Reverse Stock Split is to maintain the listing of the Company's common stock on The Nasdaq Global Market.
• If compliance is not achieved by the Compliance Date, the Company may be eligible for an additional 180-day period by applying to transfer its listing to the Nasdaq Capital Market, provided it meets other listing standards and intends to cure the deficiency via a reverse stock split if necessary.
• Failure to regain compliance or transfer to the Nasdaq Capital Market could result in a written notification of delisting, which the Company could appeal to a Nasdaq Hearings Panel.

Sentiment

Score: 3

Explanation: The company received a delisting notice due to sustained low stock price, which is a significant negative indicator. While a plan (reverse stock split) is in place, it carries inherent risks and is often viewed as a measure of last resort, reflecting underlying challenges.

Positives

• The Nasdaq notice has no immediate impact on the listing or trading of the Company's common stock.
• The Company has a defined plan (a proposed reverse stock split) already approved by its Board of Directors to address the bid price deficiency.
• RAPT Therapeutics has a substantial 180-calendar-day period, until November 17, 2025, to regain compliance.
• The Company may be eligible for an additional 180-day compliance period if it transfers its listing to the Nasdaq Capital Market.

Negatives

• The Company's common stock failed to maintain the minimum $1.00 bid price requirement for 30 consecutive trading days.
• Failure to regain compliance could lead to the delisting of the Company's common stock from Nasdaq.
• The necessity of a reverse stock split often indicates underlying stock price weakness and can be perceived negatively by investors.

Risks

• There is no assurance that the Company will be able to regain compliance with the minimum bid price requirement.
• There is no assurance that the Company will otherwise be in compliance with other Nasdaq Rules.
• There is no assurance that the proposed reverse stock split will be approved by stockholders.
• Even if the reverse stock split is effected, there is no assurance that the stock price will sustain above $1.00.
• There is no assurance that any appeal to a Nasdaq Hearings Panel would be successful if delisting occurs.
• There is no assurance that the Company would be able to evidence compliance with the terms of any extension that may be granted by the Panel.

Future Outlook

The Company intends to regain compliance with Nasdaq's minimum bid price requirement, primarily through a proposed one-for-eight reverse stock split, subject to stockholder approval. There is also a potential pathway to transfer to the Nasdaq Capital Market for an extended compliance period if initial efforts are unsuccessful.

Management Comments

• "As described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 14, 2025, the Company’s Board of Directors has approved and, subject to stockholder approval, adopted an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio of one-for-eight (the Reverse Stock Split)."
• "Stockholders will vote on the proposal related to the Reverse Stock Split at the Company’s Annual Meeting of Stockholders on May 29, 2025."
• "One of the purposes of the Reverse Stock Split and the related proposal is to maintain the listing of the Company’s common stock on The Nasdaq Global Market."

Industry Context

This filing reflects a common challenge faced by public companies, particularly in sectors like biotechnology, when their stock price falls below exchange minimums. Maintaining a Nasdaq listing is critical for liquidity, investor visibility, and access to capital markets, making compliance with listing rules a significant corporate governance priority.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face the risk of delisting, which could impact stock liquidity and value. They will also vote on the proposed reverse stock split, which could alter the number of shares they hold and potentially affect per-share metrics.
• **Employees**: While not directly impacted by this filing, a potential delisting or continued stock price weakness could affect the value of stock-based compensation and overall company morale.
• **Investors**: The delisting notice and the need for a reverse stock split signal financial distress or lack of market confidence, potentially deterring new investors and impacting existing investment decisions.

Next Steps

• Stockholders are scheduled to vote on the reverse stock split proposal at the Annual Meeting on May 29, 2025.
• The Company must achieve a closing bid price of at least $1.00 for 10 consecutive business days by November 17, 2025, to regain compliance.
• If compliance is not met, the Company may apply to transfer its listing to the Nasdaq Capital Market for an additional 180-day compliance period.
• In the event of a delisting notification, the Company could appeal Nasdaq's determination to a Nasdaq Hearings Panel.

Key Dates

Recommendation

Keywords

RAPT Therapeutics, Nasdaq, delisting, reverse stock split, bid price compliance, 8-K filing, stock market, corporate governance, biotechnology, RAPT